author-photo

Shana Thomas

Washington University in St. Louis

12

Papers

427

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

2019 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (27)
Abstract P5-21-30: Retrospective review of palbociclib (Pal) efficacy and benefit from subsequent treatments following Pal progression in patients (pts) with hormone receptor positive (HR+) and HER2 negative (HER2-) metastatic breast cancer (MBC)

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (104)
Abstract CT011: Circulating tumor DNA (ctDNA) sequencing for HER2 mutation (HER2mut) screening and response monitoring to neratinib in metastatic breast cancer (MBC)

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P5-04-02: Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

2017 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (33)